To examine the sensitivity and specificity of Hexvix cystoscopy in patients with superficial bladder cancer
• In this open study 52 patients with suspected superficial bladder cancer were investigated at 4 European centers • 50ml Hexvix® (8mM) was instilled into the bladder of patients 1 hour prior to cystoscopy and transurethral resection of the bladder • The bladder was first inspected under white light and the number and location of tumors noted. The light system was then changed to fluorescence mode (blue light) and all fluorescing lesions documented • At the end of the fluorescence inspection, 5 random biopsies per patient were taken from areas of the urothelium that appeared normal under white light • Following this, all lesions mapped in white light were biopsied or resected, followed by the same procedure with additional fluorescing lesions. Tissue from all biopsies and resections was collected for histology
AIM METHODS
• Hexvix® blue-light cystoscopy was highly efficient at detecting tumors compared with standard white light cystoscopy
Hexvix® blue-light cystoscopy is a sensitive, well-tolerated diagnostic procedure for bladder cancer that showed improved detection of bladder tumors, in particular CIS
The procedure can easily be implemented in current clinical practice 
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